drugset / Trial / NCT01461083

Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a

NCT01461083 ↗

Phase 1 Completed 19 enrolled Institute for Neurodegenerative Disorders
NaSingle-groupOpen-label

Summary

The underlying goal of this study is to assess \[18F\]MPPF PET imaging as a tool to evaluate the activity of the serotonin 5HT1a receptor in the brain of Parkinson Disease (PD) research participants.

Timeline

Start
2011-09
Primary completion
2012-11
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject [18F]MPPF Unknown 185 mbq Intravenous

Indications